Sumitomo Mitsui Trust Group Inc. Boosts Stock Holdings in Illumina, Inc. $ILMN

Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,289,810 shares of the life sciences company’s stock after acquiring an additional 54,987 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Illumina were worth $122,493,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of ILMN. Next Capital Management LLC bought a new stake in shares of Illumina during the 2nd quarter valued at $341,000. CWM LLC grew its holdings in Illumina by 112.9% during the 2nd quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock valued at $7,319,000 after buying an additional 40,676 shares in the last quarter. Generali Asset Management SPA SGR increased its position in shares of Illumina by 51.6% during the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock valued at $2,113,000 after buying an additional 7,574 shares during the period. Andra AP fonden increased its position in shares of Illumina by 426.3% during the second quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after buying an additional 83,017 shares during the period. Finally, Bourgeon Capital Management LLC lifted its holdings in shares of Illumina by 76.4% in the second quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after buying an additional 61,468 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Trading Up 1.0%

NASDAQ ILMN opened at $146.99 on Wednesday. The stock has a market cap of $22.46 billion, a P/E ratio of 32.96, a price-to-earnings-growth ratio of 2.42 and a beta of 1.41. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $153.06. The stock has a 50 day simple moving average of $131.12 and a two-hundred day simple moving average of $110.61. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the company earned $1.14 earnings per share. The firm’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Scott Gottlieb purchased 500 shares of Illumina stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ILMN. Barclays boosted their target price on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group boosted their price target on shares of Illumina from $112.00 to $130.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. Guggenheim raised their price target on Illumina from $114.00 to $144.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Finally, Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. Five research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $122.56.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Company raised FY‑2025 EPS guidance to a narrowed range of 4.760–4.790 (and set Q4 2025 EPS guidance of 1.270–1.300), which upgrades the prior outlook and supports higher near‑term earnings expectations.
• Positive Sentiment: Illumina introduced the “Billion Cell Atlas,” a genome‑wide perturbation dataset intended to accelerate AI‑driven drug discovery — a strategic product that strengthens Illumina’s addressable market in pharma AI and could drive licensing/data‑services revenue. Illumina introduces Billion Cell Atlas
• Positive Sentiment: Media coverage and analyst notes highlight Illumina’s Connected Multiomics platform and a recent chief medical officer appointment, reinforcing execution on higher‑margin, software/data offerings that can lift long‑term valuation multiples. Assessing Illumina (ILMN) Valuation
• Neutral Sentiment: Illumina released preliminary unaudited Q4 and FY‑2025 results ahead of its full report (earnings will be released Feb. 5, 2026), a routine timing/communication step that gives investors early visibility but keeps final numbers pending. Preliminary Unaudited Financial Results
• Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference; the transcript provides detail on strategy and product rollout but did not contain surprise guidance beyond the updated ranges. J.P. Morgan Presentation Transcript
• Negative Sentiment: ARK/ARK Invest trimmed Illumina holdings (reported block sale of roughly $13.3M), a signal that may weigh on sentiment given ARK’s visibility among growth investors. Cathie Wood Sells Meta and Illumina

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.